Recent Updates
Recently added Catalysts

AN2690

Phase 2

Onychomycosis | Small molecule | Other |Pfizer, Inc.|Last Updated: Apr 9, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials6
Total Enrollment221
FDA Designations
No designations recorded
Clinical Trials (6)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00679601Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)PHASE2 COMPLETED 20Mar 31, 2007May 31, 2007Feb 20, 20181 United States
NCT01278394Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailPHASE2 COMPLETED 29Mar 1, 2007Jul 1, 2008Dec 6, 20182 Mexico
NCT00680134Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With OnychomycosisPHASE2 COMPLETED 60Jun 30, 2006Aug 31, 2007Feb 20, 20187 United States
NCT00680160Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)PHASE2 COMPLETED 15Apr 30, 2006May 9, 2007Feb 21, 20191 United States
NCT00679523Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailPHASE2 COMPLETED 60Nov 1, 2005Feb 1, 2007Nov 14, 20189 Mexico
NCT00680095Cumulative Irritation TestPHASE1 COMPLETED 37Jan 22, 2007Feb 19, 2007Apr 9, 20191 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Plasma concentration of AN2690 in plasma and the concentration of AN2690 in urine over time
Days 0, 1, 14, 15, and 28
Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360
Day 360

Proportion of subjects with a clinical assessment of a clear (completely normal) nail unit plus a negative fungal culture from the treatment-targeted toenail at Day 360.

Complete or partial clinical evidence of great toenail clearance or at least 2 mm of fungal clear linear great toenail growth plus a negative fungal culture from the treatment targeted toenail at the End-of-treatment (Day 180)
Day 180
Efficacy measures of linear toenail growth, fungal culture results, KOH results, and clear toenail
Days 0, 14, 28, 42, 84, 120, 150, 180, 240, 300, and 360
A calculated endpoint of treatment response at Day 180 comprised of the ISGA, clear nail growth and fungal culture results
Day 180
Severe irritation (Grade 3 or 4) observed at any site
Daily for 21 days
Secondary Endpoints
Efficacy measures of linear toenail growth, fungal culture results, KOH results, and clear toenail growth
Days 0, 14, 28, and 42
Safety and tolerance assessed by application site reactions, adverse events, vital signs, physical examinations, and 12-lead EKG
Days 0-28, and 42
Clear Nail Growth of the Targeted Toenail
Day 360
Unlock Study Endpoints
Study Design & Arms
MaskingNONE
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Group 1EXPERIMENTALAN2690 Solution, 5.0%
Group/Cohort 1EXPERIMENTALAN2690 1% Solution (30 subjects)
Group/Cohort 2EXPERIMENTALAN2690 5% Solution (30 subjects)
Group 2EXPERIMENTALAN2690 Solution, 7.5%
AEXPERIMENTALAN2690 Solution, 2.5%
BEXPERIMENTALAN2690 Solution, 7.5%
CEXPERIMENTALAN2690 Solution, 5.0%
DACTIVE_COMPARATORAN2690 Solution, Vehicle
EACTIVE_COMPARATORSodium Lauryl Sulfate, 0.5%
Interventions
NameTypeDescription
AN2690DRUGAN2690 7.5% Solution, once daily for 28 days
AN2690 Solution, 5.0%DRUGOnce daily application for 360 days
AN2690 Solution, 7.5%DRUGOnce daily application for 180 days
AN2690 Solution, VehicleOTHERAN2690 Solution, Vehicle, Daily for up to 21 days
Sodium Lauryl Sulfate, 0.5%OTHERSodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Male or female ≥18 and ≤65 * BMI between 18.5 and 35 inclusive * Moderate to severe onychomycosis involving ≥80% of both great toenails, as determined by visual inspection after the nail has been trimmed * Combined thickness of the nail plate and nail bed of each great toenail...

Countries:United StatesMexico
Unlock Eligibility Criteria